{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:51:01Z","timestamp":1781790661781,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This descriptive seroepidemiology study characterized group B Streptococcus (GBS) capsular antibody levels in pregnant individuals and their newborns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Healthy US and South African \u226518-year-olds at \u226534 weeks of pregnancy were enrolled. Exploratory analyses evaluated GBS serotype-specific (Ia, Ib, II, III, IV, and V) anticapsular polysaccharide (CPS) immunoglobulin G (IgG) geometric mean concentrations (GMCs) before and at delivery and in cord blood; newborn-to-maternal transplacental transfer ratios were determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 722 maternal (United States, n = 273; South Africa, n = 449) and 592 newborn participants (n = 251; n = 341). Maternal GBS anti-CPS IgG GMCs were similar before and at delivery. A trend for higher GMCs (serotypes Ia, Ib, II, and III) among South African compared with US maternal participants was seen. As in maternal participants, GMCs for serotypes Ia and III trended higher among South African compared with US newborns. Mean transplacental transfer ratios were higher for US newborn\u2013maternal pairs compared with South African dyads. Transplacental transfer ratios for serotypes Ia and Ib were &amp;gt;1 for US pairs. Among US participants, there was a trend for higher transplacental transfer ratios among White versus Black participants. Maternal hypergammaglobulinemia (gamma globulin &amp;gt;1.35\u2005g\/dL) was observed in 23.8% of South African participants and in no US participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Group B Streptococcus serotype-specific IgG GMCs varied by region and serotype; reasons for observed regional differences are likely multifactorial, including variations in baseline antibodies and transplacental transfer efficiency. Understanding these variations may inform efforts for maternal immunization strategies aimed at enhancing neonatal antibody concentrations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag340","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:36:00Z","timestamp":1781004960000},"source":"Crossref","is-referenced-by-count":0,"title":["Maternal and Newborn Group B\n                    <i>Streptococcus<\/i>\n                    Serology in the United States and South Africa"],"prefix":"10.1093","volume":"13","author":[{"given":"Barbara A","family":"Pahud","sequence":"first","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0636","authenticated-orcid":false,"given":"Shabir A","family":"Madhi","sequence":"additional","affiliation":[{"name":"South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center , Oakland, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cai","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid L","family":"Scully","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gaylord","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Feng","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Qing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A","family":"Swanson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Munjal","sequence":"additional","affiliation":[{"name":"Pfizer Vaccines, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026061808522988500_ofag340-B1","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the burden of group B Streptococcal disease worldwide for pregnant women, stillbirths, and children","volume":"65","author":"Seale","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026061808522988500_ofag340-B2","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.jmb.2019.01.035","article-title":"The double life of group B Streptococcus: asymptomatic colonizer and potent pathogen","volume":"431","author":"Armistead","year":"2019","journal-title":"J Mol Biol"},{"key":"2026061808522988500_ofag340-B3","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1016\/S2214-109X(22)00093-6","article-title":"Group B Streptococcus infection during pregnancy and infancy: estimates of regional and global burden","volume":"10","author":"Gon\u00e7alves","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026061808522988500_ofag340-B4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MOP.0000000000001223","article-title":"20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention","volume":"35","author":"Paul","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"2026061808522988500_ofag340-B5","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/cid\/cix658","article-title":"Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses","volume":"65","author":"Russell","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026061808522988500_ofag340-B6","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.gpp3-0007-2018","article-title":"Group B Streptococcus (Streptococcus agalactiae)","volume":"7","author":"Raabe","year":"2019","journal-title":"Microbiol Spectr"},{"key":"2026061808522988500_ofag340-B7","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.gpp3-0001-2017","article-title":"Surface structures of group B Streptococcus important in human immunity","volume":"7","author":"Paoletti","year":"2019","journal-title":"Microbiol Spectr"},{"key":"2026061808522988500_ofag340-B8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJM197604012941404","article-title":"Correlation of maternal antibody deficiency with susceptibility to neonatal group B Streptococcal infection","volume":"294","author":"Baker","year":"1976","journal-title":"N Engl J Med"},{"key":"2026061808522988500_ofag340-B9","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2015.10.019","article-title":"Correlates of protection of serotype-specific capsular antibody and invasive group B Streptococcus disease in South African infants","volume":"33","author":"Dangor","year":"2015","journal-title":"Vaccine"},{"key":"2026061808522988500_ofag340-B10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/cid\/ciw377","article-title":"The protective value of maternal group B Streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in European maternal sera","volume":"63","author":"Fabbrini","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026061808522988500_ofag340-B11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1086\/323350","article-title":"Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study","volume":"184","author":"Lin","year":"2001","journal-title":"J Infect Dis"},{"key":"2026061808522988500_ofag340-B12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/422756","article-title":"Level of maternal IgG anti-group B Streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen","volume":"190","author":"Lin","year":"2004","journal-title":"J Infect Dis"},{"key":"2026061808522988500_ofag340-B13","doi-asserted-by":"crossref","first-page":"e1170","DOI":"10.1093\/cid\/ciaa1873","article-title":"Association of group B Streptococcus (GBS) serum serotype-specific anticapsular immunoglobulin G concentration and risk reduction for invasive GBS disease in South African infants: an observational birth-cohort, matched case-control study","volume":"73","author":"Madhi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026061808522988500_ofag340-B14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiz062","article-title":"A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B Streptococcal infections by maternal immunization","volume":"220","author":"Buurman","year":"2019","journal-title":"J Infect Dis"},{"key":"2026061808522988500_ofag340-B15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1473-3099(20)30478-3","article-title":"Safety and immunogenicity of a novel hexavalent group B Streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1\/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial","volume":"21","author":"Absalon","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026061808522988500_ofag340-B16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa2116045","article-title":"Potential for maternally administered vaccine for infant group B Streptococcus","volume":"389","author":"Madhi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061808522988500_ofag340-B17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ejogrb.2020.06.024","article-title":"Group B streptococcal disease in the mother and newborn-A review","volume":"252","author":"Steer","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026061808522988500_ofag340-B18","doi-asserted-by":"crossref","first-page":"985646","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2026061808522988500_ofag340-B19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf386","article-title":"Dynamics of respiratory syncytial virus illness and serology during pregnancy and infancy in the United States and South Africa","volume":"12","author":"Madhi","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026061808522988500_ofag340-B20","doi-asserted-by":"crossref","first-page":"2311480","DOI":"10.1080\/21645515.2024.2311480","article-title":"Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B Streptococcus capsular polysaccharides","volume":"20","author":"Gaylord","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026061808522988500_ofag340-B21","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1097\/INF.0000000000002364","article-title":"Hypergammaglobulinemia and impaired transplacental transfer of respiratory syncytial virus antibody in Papua New Guinea","volume":"38","author":"Atwell","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026061808522988500_ofag340-B22","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3389\/fimmu.2020.01920","article-title":"Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors","volume":"11","author":"Clements","year":"2020","journal-title":"Front Immunol"},{"key":"2026061808522988500_ofag340-B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9378(80)90383-X","article-title":"The natural history of group B Streptococcal colonization in the pregnant woman and her offspring. II. Determination of serum antibody to capsular polysaccharide from type III, group B Streptococcus","volume":"137","author":"Baker","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"2026061808522988500_ofag340-B24","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0022-3476(84)80564-8","article-title":"Transplacental passage of IgG antibody to group B Streptococcus serotype Ia","volume":"104","author":"Boyer","year":"1984","journal-title":"J Pediatr"},{"key":"2026061808522988500_ofag340-B25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3389\/fimmu.2017.01641","article-title":"They are what you eat: can nutritional factors during gestation and early infancy modulate the neonatal immune response?","volume":"8","author":"Prentice","year":"2017","journal-title":"Front Immunol"},{"key":"2026061808522988500_ofag340-B26","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.vaccine.2022.06.034","article-title":"Biological factors that may impair transplacental transfer of RSV antibodies: implications for maternal immunization policy and research priorities for low- and middle-income countries","volume":"40","author":"Atwell","year":"2022","journal-title":"Vaccine"},{"key":"2026061808522988500_ofag340-B27","first-page":"1","article-title":"Prevention of perinatal group B Streptococcal disease\u2013revised guidelines from CDC, 2010","volume":"59","author":"Verani","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2026061808522988500_ofag340-B28","doi-asserted-by":"crossref","first-page":"100897","DOI":"10.1016\/S2666-5247(24)00129-0","article-title":"Prevalence of group B Streptococcus colonisation in mother-newborn dyads in low-income and middle-income South Asian and African countries: a prospective, observational study","volume":"5","author":"Kwatra","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026061808522988500_ofag340-B29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12879-019-3809-6","article-title":"Prevalence and capsular type distribution of Streptococcus agalactiae isolated from pregnant women in Namibia and South Africa","volume":"19","author":"Mukesi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026061808522988500_ofag340-B30","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/pathogens10121606","article-title":"Group B streptococcal colonization in African countries: prevalence, capsular serotypes, and molecular sequence types","volume":"10","author":"Shabayek","year":"2021","journal-title":"Pathogens"},{"key":"2026061808522988500_ofag340-B31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2666-5247(24)00038-7","article-title":"Association between anti-capsular IgG levels at birth and risk of invasive group B Streptococcus disease in Finnish newborns: a retrospective case-control study","volume":"5","author":"Saukkoriipi","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026061808522988500_ofag340-B32","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1016\/j.vaccine.2021.10.022","article-title":"Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease","volume":"39","author":"Dangor","year":"2021","journal-title":"Vaccine"},{"key":"2026061808522988500_ofag340-B33","doi-asserted-by":"crossref","first-page":"9381","DOI":"10.1038\/s41467-025-64324-y","article-title":"A US case-control study to estimate infant group B Streptococcal disease serological thresholds of risk-reduction","volume":"16","author":"Rhodes","year":"2025","journal-title":"Nat Commun"},{"key":"2026061808522988500_ofag340-B34","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1128\/IAI.06232-11","article-title":"L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B Streptococci","volume":"80","author":"Fujieda","year":"2012","journal-title":"Infect Immun"},{"key":"2026061808522988500_ofag340-B35","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.vaccine.2024.04.014","article-title":"Antibody kinetics between birth and three months of life in healthy infants with natural exposure to group B Streptococcus: a UK cohort study","volume":"42","author":"Karampatsas","year":"2024","journal-title":"Vaccine"},{"key":"2026061808522988500_ofag340-B36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12874-022-01529-5","article-title":"Estimation of invasive group B streptococcus disease risk in young infants from case-control serological studies","volume":"22","author":"Izu","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2026061808522988500_ofag340-B37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14760584.2018.1496021","article-title":"Systematic review of the clinical development of group B Streptococcus serotype-specific capsular polysaccharide-based vaccines","volume":"17","author":"Dzanibe","year":"2018","journal-title":"Expert Rev Vaccines"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag340\/68515273\/ofag340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag340\/68515273\/ofag340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag340\/68515273\/ofag340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:52:37Z","timestamp":1781787157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag340\/8706628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag340","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag340"}}